Invivyd Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People

Invivyd Inc. has announced positive initial data from its ongoing Phase 1 clinical trial of VYD222, a monoclonal antibody candidate in development for the prevention of symptomatic COVID-19 in immunocompromised people. The early serum samples from the first cohort showed strong neutralization activity against Omicron XBB.1.5, one of the dominant SARS-CoV-2 variants circulating globally. Higher V..